17 research outputs found
Informed consent zum record linkage: best practice und Mustertexte
Ausgangssituation: Die informierte Einwilligung ("Informed Consent") stellt den Königsweg fĂŒr die Nutzung personenbezogener Daten dar. Gute Beispiele und Orientierungshilfen sind z.B. bei der Deutsche Gesellschaft fĂŒr Medizinische Informatik, Biometrie und Epidemiologie (GMDS) bzw. der Medizininformatik Initiative (MII) zu finden. FĂŒr die prospektive VerknĂŒpfung eines personenbezogenen Datensatzes mit weiteren personenbezogenen Daten (Record Linkage) â z.B. die Anreicherung von PrimĂ€rdaten einer epidemiologischen Studie mit SekundĂ€rdaten aus der Krankenversorgung bzw. von KostentrĂ€gern â gestaltet sich das Vorgehen hinsichtlich der Datenschutzanforderungen als sehr komplex. Studien in der Onkologie bzw. der Infektionsforschung, bei meldepflichtigen Erkrankungen bzw. im COVID-19-Umfeld könnten als Erlaubnistatbestand das jeweilige Krebsregistergesetz bzw. das Infektionsschutzgesetz heranziehen. Epidemiologische Studien erfordern i.d.R. diesbezĂŒglich einen Informed Consent zum Record Linkage. Es kann allerdings nicht davon ausgegangen werden, dass alle Betroffenen diesen Informed Consent dazu uneingeschrĂ€nkt erteilen. Zudem kann eine solche Einwilligung widerrufen werden. Aufgrund der sich daraus ergebenden Anforderungen werden fĂŒr zukĂŒnftige Projekte Mustertexte fĂŒr die informierte Einwilligung zum Record Linkage als Grundlage fĂŒr studienspezifische EinwilligungserklĂ€rungen â nicht nur fĂŒr COVID-19 â bereitgestellt. Diese basieren auf erprobten AufklĂ€rungstexten und Formulierungen aus der CoVerlauf-Studie sowie der NAKO Gesundheitsstudie
Consenso brasileiro para o tratamento da esclerose mĂșltipla : Academia Brasileira de Neurologia e ComitĂȘ Brasileiro de Tratamento e Pesquisa em Esclerose MĂșltipla
O crescent arsenal terapĂȘutico na esclerose mĂșltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do ComitĂȘ Brasileiro de Tratamento e Pesquisa em Esclerose MĂșltipla e do Departamento CientĂfico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que Ă© melhor para cada paciente, com base em evidĂȘncias e prĂĄticas atualizadas. Por meio deste documento, propomos recomendaçÔes prĂĄticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratĂ©gias de tratamento na EM.The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS
Second intention healing after wide local excision of soft tissue sarcomas in the distal aspects of the limbs in dogs: 31 cases (2005â2012)
Adverse events and outcomes in dogs with appendicular osteosarcoma treated with limb amputation and a single subcutaneous infusion of carboplatin
Preparation of Single Site Catalysts on Oxides and Metals Prepared via Surface Organometallic Chemistry
International audienc
Informed consent zum record linkage
Ausgangssituation: Die informierte Einwilligung ("Informed Consent") stellt den Königsweg fĂŒr die Nutzung personenbezogener Daten dar. Gute Beispiele und Orientierungshilfen sind z.B. bei der Deutsche Gesellschaft fĂŒr Medizinische Informatik, Biometrie und Epidemiologie (GMDS) bzw. der Medizininformatik Initiative (MII) zu finden. FĂŒr die prospektive VerknĂŒpfung eines personenbezogenen Datensatzes mit weiteren personenbezogenen Daten (Record Linkage) â z.B. die Anreicherung von PrimĂ€rdaten einer epidemiologischen Studie mit SekundĂ€rdaten aus der Krankenversorgung bzw. von KostentrĂ€gern â gestaltet sich das Vorgehen hinsichtlich der Datenschutzanforderungen als sehr komplex. Studien in der Onkologie bzw. der Infektionsforschung, bei meldepflichtigen Erkrankungen bzw. im COVID-19-Umfeld könnten als Erlaubnistatbestand das jeweilige Krebsregistergesetz bzw. das Infektionsschutzgesetz heranziehen. Epidemiologische Studien erfordern i.d.R. diesbezĂŒglich einen Informed Consent zum Record Linkage. Es kann allerdings nicht davon ausgegangen werden, dass alle Betroffenen diesen Informed Consent dazu uneingeschrĂ€nkt erteilen. Zudem kann eine solche Einwilligung widerrufen werden. Aufgrund der sich daraus ergebenden Anforderungen werden fĂŒr zukĂŒnftige Projekte Mustertexte fĂŒr die informierte Einwilligung zum Record Linkage als Grundlage fĂŒr studienspezifische EinwilligungserklĂ€rungen â nicht nur fĂŒr COVID-19 â bereitgestellt. Diese basieren auf erprobten AufklĂ€rungstexten und Formulierungen aus der CoVerlauf-Studie sowie der NAKO Gesundheitsstudie
Rutin inhibits proliferation, attenuates superoxide production and decreases adhesion and migration of human cancerous cells
International audienceLung and colorectal cancer are the principal causes of death in the world. Rutin, an active flavonoid compound, is known for possessing a wide range of biological activities. In this study, we examined the effect of rutin on the viability, superoxide anion production, adhesion and migration of human lung (A549) and colon (HT29 and Caco-2) cancer cell lines. In order to control the harmlessness of the tested concentrations of rutin, the viability of cancer cell lines was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. ROS generation was measured by lucigenin chemiluminescence detecting superoxide ions. To investigate the effect of rutin on the behavior of human lung and colon cancer cell lines, we performed adhesion assays, using various purified extracellular matrix (ECM) proteins. Finally, in vitro cell migration assays were explored using modified Boyden chambers. The viability of cancerous cells was inhibited by rutin. It also significantly attenuated the superoxide production in HT29 cells. In addition, rutin affected adhesion and migration of A549 and HT29 cell. These findings indicate that rutin, a natural molecule, might have potential as anticancer agent against lung and colorectal carcinogenesis
Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process.
Human alpha-synuclein is a small soluble protein abundantly expressed in neurons. It represents the principal constituent of Lewy bodies, the main neuropathological characteristic of Parkinson's disease. The fragment corresponding to the region 61-95 of the protein, originally termed NAC (non-amyloid-beta component), has been found in amyloid plaques associated with Alzheimer's disease, and several reports suggest that this region represents the critical determinant of the fibrillation process of alpha-synuclein. To better understand the aggregation process of alpha-synuclein and the role exerted by the biological membranes, we studied the structure and the topology of the NAC region in the presence of SDS micelles, as membrane-mimetic environment. To overcome the low solubility of this fragment, we analyzed a recombinant polypeptide corresponding to the sequence 57-102 of alpha-synuclein, which includes some charged amino acids flanking the NAC region. Three distinct helices are present, separated by two flexible stretches. The first two helices are located closer to the micelle surface, whereas the last one seems to penetrate more deeply into the micelle. On the basis of the structural and topological results presented, a possible pathway for the aggregation process is suggested. The structural information described in this work may help to identify the appropriate target to reduce the formation of pathological alpha-synuclein aggregation
TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is caused by pathogenic variants in the DMD gene leading to the lack of dystrophin. Variability in the disease course suggests that other factors influence disease progression. With this study we aimed to identify genetic factors that may account for some of the variability in the clinical presentation. We compared whole-exome sequencing (WES) data in 27 DMD patients with extreme phenotypes to identify candidate variants that could affect disease progression. Validation of the candidate SNPs was performed in two independent cohorts including 301 (BIO-NMD cohort) and 109 (CINRG cohort of European ancestry) DMD patients, respectively. Variants in the Tctex1 domain containing 1 (TCTEX1D1) gene on chromosome 1 were associated with age of ambulation loss. The minor alleles of two independent variants, known to affect TCTEX1D1 coding sequence and induce skipping of its exon 4, were associated with earlier loss of ambulation. Our data show that disease progression of DMD is affected by a new locus on chromosome 1 and demonstrate the possibility to identify genetic modifiers in rare diseases by studying WES data in patients with extreme phenotypes followed by multiple layers of validation